Survival among women with borderline ovarian tumors and ovarian carcinoma

Abstract

BACKGROUND. Serous and mucinous ovarian tumors of low malignant potential (LMP-S and LMP-M, respectively) are noninvasive tumors that portend excellent survival when confined to the ovary. Comparison of the survival for women with LMP tumors staged as distant with women who have carcinoma may have important implications for diagnostic terminology and clinical management. METHODS. The authors compared relative survival rates among patients diagnosed with ovarian tumors during the period 1988-1999 (with follow-up through 2000) by histologic type, disease stage, tumor grade (for carcinomas), and patient age, using data from the Surveillance, Epidemiology, and End Results Program. RESULTS. The overall relative survival rate at 10 years (Ϯ 1.96 standard errors) was 96.9% Ϯ 2.3% for women with LMP-S tumors, 30.4% Ϯ 1.7% for women with serous carcinoma (CA-S); 94.0% Ϯ 3.1% for women with LMP-M tumors, and 64.7% Ϯ 3.4% for women with mucinous carcinoma (CA-M). The survival rate at 10 years for women with distant-stage LMP-S tumors was 89.9% Ϯ 5.3%, compared with 96.1% Ϯ 8.6% for women with well differentiated, localized CA-S. The survival rate for women with distant-stage LMP-M tumors at 5 years was 85.5% Ϯ 9.0%, compared with 95.5% Ϯ 3.4% for women with well differentiated, localized CA-M (data for 10 years were limited). Mucinous ovarian neoplasms were associated with an excess of second malignancies of the digestive tract. CONCLUSIONS. Relative survival among women with distant-stage LMP tumors was not 100% and resembled the survival of women who had carcinoma exhibiting favorable prognostic features (localized stage). Future studies of women with high-stage LMP tumors are required to clarify the pathogenesis of extraovarian lesions and their implications for management and prognosis.

Gene expression profiling of human ovarian tumours

“…A more recent study by Trimble et al (2002) found FIGO stage to be associated with survival in 2818 women with borderline ovarian tumours. Similarly, Sherman et al (2004) reported reduced 10 year survival in distant stage vs localised disease in a group of approximately 4500 borderline ovarian cancer patients. To date, there have been few comprehensive analyses of molecular determinants of prognosis.…”

Clinical outcome and risk factors for recurrence in borderline ovarian tumours

“…It has been shown that the 5-year survival rate was 95 -97% for stage I and 65 -87% for stages II and III (Trope et al, 2000;Trimble et al, 2002;Sherman et al, 2004) suggesting that the prognosis for borderline ovarian tumours depends on extraovarian extension of the tumour. In addition, prognostic factors included clinical stage, histopathological subtype, and residual tumour, but the surgical method was not regarded as a prognostic factor (Trope et al, 2000;Gilks, 2003).…”

A distinct molecular profile associated with mucinous epithelial ovarian cancer

“…Although less common, advanced MOC is associated with a very poor survival that surpasses the poor prognosis for women with advanced stage serous ovarian cancer (Sherman et al, 2004). Accumulating pathological and epidemiological evidence supports a progression model of MOC, from benign cysts to borderline tumours to invasive adenocarcinoma (Feeley and Wells, 2001;Shih and Kurman, 2004).…”

“…The majority of mucinous ovarian cancers (MOC) are diagnosed at an early stage, either as borderline (atypical proliferative) tumours or low-grade carcinomas, and have an excellent prognosis (Sherman et al, 2004). Although less common, advanced MOC is associated with a very poor survival that surpasses the poor prognosis for women with advanced stage serous ovarian cancer (Sherman et al, 2004).…”